Publications by authors named "Katherine G Madden"
Background: Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility and is not used in routine clinical practice.
Methods: Tumor specimens from 56 patients with mRCC who received nivolumab were evaluated for PD-L1, cell proliferation (targeted RNA-seq), and outcome.
Background: Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1).
View Article and Find Full Text PDFBackground: PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a different ICI. We set to test if next generation RNA sequencing (RNA-seq) is a robust method to determine PD-L1 mRNA expression levels and furthermore, efficacy of predicting response to ICIs as compared to routinely used, standardized IHC procedures.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, yet their effectiveness varies among patients, and current biomarkers like PD-L1 and mutational burden are not fully reliable.
- A study evaluated various immune factors in melanoma patients, integrating data to create a Response Score (RS) that better predicts patient outcomes than existing methods.
- Results showed that RS outperformed PD-L1 expression and mutational burden in predicting responses to ICIs, highlighting the potential of comprehensive immune profiling for improving treatment decisions.